Osteoarthritis (OA) is a chronic inflammation of the joints, and is produced by cartilage damage, among other factors. Chile is the third country in Latin America with a higher prevalence of OA, with the knee being the most affected joint.
With the purpose of finding a new therapeutic option for this pathology, Cells for Cells developed Cellistem® OA, an allogeneic cell therapy that allows an 80% reduction of pain and a substantially improved joint function, compared to traditional therapy, both at 6 months and after a year of follow-up. Cellistem® OA is applied in a simple and ambulatory way, through an intra-articular infiltration.
These successful results are supported by the first Latin American study of Phases I/II, carried out entirely at the Universidad de los Andes Clinic by the Traumatology and Rheumatology team, led by physicians Dr. José Matas and Dr. Mario Orrego. To date, more than 40 patients with knee, hip, ankle and wrist OA have been treated with excellent results.
Dr. José Matas, besides being one of the leaders of the clinical study, suffers knee OA, so he decided to treat himself with Cellistem® OA therapy, and in this respect, he says that “the functional results are extraordinary, and besides I have no pain anymore”.